Novel PPARγ partial agonists with weak activity and no cytotoxicity; Identified by a simple PPARγ ligand screening system

Molecular and Cellular Biochemistry

Volumn 358, Issue 1-2, 2011, Pages 75-83

  Cho, Min Chul ^a   Lee, Dong Hun ^a   Kim, Eun Jin ^a   Lee, Jee Young ^a   Kang, Jeong Woo ^a   Song, Jong Hwan ^b   Chong, Youhoon ^a   Kim, Yangmi ^a   Hong, Jin Tae ^c   Yoon, Do Young ^a  

^a Konkuk University   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

^c Chungbuk National University   (South Korea)

Author keywords

Chemical library including flavonoid derivatives; Docking; Ligand; Metabolic disorders; Partial agonist; PPAR

Indexed keywords

LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROID RECEPTOR COACTIVATOR 1;

ADIPOGENESIS; ANIMAL; ARTICLE; CELL DEATH; CELL STRAIN 3T3; CELL STRAIN HEK293; CHEMICAL STRUCTURE; DRUG POTENTIATION; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR WEIGHT; MOUSE; PROTEIN BINDING; TRANSCRIPTION INITIATION;

3T3-L1 CELLS; ADIPOGENESIS; ANIMALS; CELL DEATH; DRUG EVALUATION, PRECLINICAL; HEK293 CELLS; HUMANS; LIGANDS; MICE; MODELS, MOLECULAR; MOLECULAR WEIGHT; NUCLEAR RECEPTOR COACTIVATOR 1; PPAR GAMMA; PROTEIN BINDING; TRANSCRIPTIONAL ACTIVATION;

EID: 84879791655     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-011-0923-1     Document Type: Article

References (37)

1. Giguere V (1999) Orphan nuclear receptors: from gene to function. Endocr Rev 20(5):689-725
2. Lowell BB (1999) PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function. Cell 99(3):239-242
3. Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20(5): 649-688
4. Willson TM, Lambert MH, Kliewer SA (2001) Peroxisome proliferator- activated receptor gamma and metabolic disease. Annu Rev Biochem 70:341-367. doi:10.1146/annurev.biochem.70.1.341
5. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272(6):3406-3410
6. Houseknecht KL, Cole BM, Steele PJ (2002) Peroxisome proliferator- activated receptor gamma (PPARgamma) and its ligands: a review. Domest Anim Endocrinol 22(1):1-23
7. Tontonoz P, Graves RA, Budavari AI, Erdjument-Bromage H, Lui M, Hu E, Tempst P, Spiegelman BM (1994) Adipocytespecific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. Nucleic Acids Res 22(25):5628-5634
8. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM (1994) mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8(10):1224-1234
9. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395(6698):137-143. doi:10.1038/25931
10. Heery DM, Kalkhoven E, Hoare S, Parker MG (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387(6634):733-736. doi:10.1038/42750
11. Cho MC, Lee K, Paik SG, Yoon DY (2008) Peroxisome proliferators-activated receptor (PPAR) modulators and metabolic disorders. PPAR Res 2008:679137. doi:10.1155/2008/679137
12. Cho MC, Lee WS, Hong JT, Park SW, Moon DC, Paik SG, Yoon DY (2005) 5-(3,5-Di-tert-butyl-4-hydroxybenzylidene) thiazolidine-2,4-dione modulates peroxisome proliferators-activated receptor gamma in 3T3-L1 adipocytes: roles as a PPARgamma ligand. Mol Cell Endocrinol 242(1-2):96-102. doi:10.1016/j.mce. 2005.08.005
13. Lee HS, Cho MC, Baek TW, Choe YK, Kim JW, Hong JT, Myung PK, Paik SG, Yoon DY (2005) Epitope analysis of PPARgamma monoclonal antibody Pgamma48.34A and its application for screening PPARgamma ligands. J Immunol Methods 296(1-2):125-134. doi:10.1016/j.jim.2004.11.011
14. Cho MC, Yoon HE, Kang JW, Park SW, Yang Y, Hong JT, Song EY, Paik SG, Kim SH, Yoon DY (2006) A simple method to screen ligands of peroxisome proliferator-activated receptor delta. Eur J Pharm Sci 29(5):355-360. doi:10.1016/j.ejps.2006.07.003
15. Lee JY, Kim Y (2005) Comparative homology modeling and ligand docking study of human catechol-O-methyltransfease for antiparkinson drug desing. Bull Korean Chem Soc 26:1695-1700
16. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19:1639-1662
17. Cho MC, Lee S, Choi HS, Yang Y, Tae Hong J, Kim SJ, Yoon DY (2009) Optimization of an enzyme-linked immunosorbent assay to screen ligand of Peroxisome proliferator-activated receptor alpha. Immunopharmacol Immunotoxicol 31(3):459-467. doi:10.1080/08923970902785246
18. Glass CK, Rosenfeld MG (2000) The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14(2): 121-141
19. Yu S, Reddy JK (2007) Transcription coactivators for peroxisome proliferator-activated receptors. Biochim Biophys Acta 1771(8): 936-951. doi:10.1016/j.bbalip.2007.01.008
20. Berger JP, Akiyama TE, Meinke PT (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26(5): 244-251. doi:10.1016/j.tips.2005. 03.003
21. Knouff C, Auwerx J (2004) Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 25(6):899-918. doi: 10.1210/er.2003-0036
22. Zoete V, Grosdidier A, Michielin O (2007) Peroxisome proliferator- activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 1771(8):915-925. doi:10.1016/j.bbalip.2007.01.007
23. Kuhn B, Hilpert H, Benz J, Binggeli A, Grether U, Humm R, Marki HP, Meyer M, Mohr P (2006) Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists. Bioorg Med Chem Lett 16(15):4016-4020. doi:10.1016/j.bmcl.2006.05.007
24. Lewis SN, Bassaganya-Riera J, Bevan DR (2010) Virtual screening as a technique for PPAR modulator discovery. PPAR Res 2010:861238. doi:10.1155/2010/861238
25. Liu LS, Tanaka H, Ishii S, Eckel J (1998) The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes. Endocrinology 139(11):4531-4539
26. Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H, Lazar MA (1998) A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. J Biol Chem 273(49):32679-32684
27. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43(5):993-1002. doi:10.1161/01.HYP.0000123072.34629.57
28. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U (2005) Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54(12):3442-3452
29. Allen T, Zhang F, Moodie SA, Clemens LE, Smith A, Gregoire F, Bell A, Muscat GE, Gustafson TA (2006) Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity. Diabetes 55(9):2523-2533. doi:10.2337/db06-0618
30. Zhang F, Lavan BE, Gregoire FM (2007) Selective modulators of PPAR-gamma activity: molecular aspects related to obesity and side-effects. PPAR Res 2007:32696. doi:10.1155/2007/32696
31. Fujimura T, Sakuma H, Konishi S, Oe T, Hosogai N, Kimura C, Aramori I, Mutoh S (2005) FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. J Pharmacol Sci 99(4):342-352
32. Minoura H, Takeshita S, Ita M, Hirosumi J, Mabuchi M, Kawamura I, Nakajima S, Nakayama O, Kayakiri H, Oku T, Ohkubo-Suzuki A, Fukagawa M, Kojo H, Hanioka K, Yamasaki N, Imoto T, Kobayashi Y, Mutoh S (2004) Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. Eur J Pharmacol 494(2-3):273-281. doi:10.1016/j.ejphar.2004.04.038
33. Gross B, Staels B (2007) PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab 21(4):687-710. doi:10.1016/j.beem.2007.09.004
34. Acton JJ III, Akiyama TE, Chang CH, Colwell L, Debenham S, Doebber T, Einstein M, Liu K, McCann ME, Moller DE, Muise ES, Tan Y, Thompson JR, Wong KK, Wu M, Xu L, Meinke PT, Berger JP, Wood HB (2009) Discovery of (2R)-2-(3-{3-[(4-methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy) -1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume. J Med Chem 52(13):3846-3854. doi:10.1021/jm900097m
35. Henriksen K, Byrjalsen I, Nielsen RH, Madsen AN, Larsen LK, Christiansen C, Beck-Nielsen H, Karsdal MA (2009) A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats. Eur J Pharmacol 616(1-3):340-345. doi:10.1016/j.ejphar. 2009.06.051
36. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT Jr, McKee DD, Moore JT, Willson TM (2001) Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 98(24):13919-13924. doi: 10.1073/pnas.241410198
37. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, Chamaillard M, Desreumaux P (2006) PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 55(9):1341-1349. doi:10.1136/gut.2006.093484